

Product Pipeline

	Phase I	Phase II	Phase III	Registration	Approval
<u>Neratinib: Tyrosine kinase inhibitor</u>					
HER2+ Breast Cancer					
Extended adjuvant <i>Neratinib monotherapy</i>	ExteNET (Phase III HER2+ EBC*)				
Metastatic <i>Monotherapy or combo therapy</i>	NALA (Phase III 3 rd Line HER2+ MBC**)				
Metastatic w/ brain mets <i>Monotherapy or combo therapy</i>	TBCRC-022 (T-DM1 + neratinib)				
<u>Alisertib: Aurora kinase A inhibitor</u>					
HRc+*** HER2-negative MBC	TBCRC-041 (fulvestrant + alisertib)				
	ALISCA™-Breast1 (alisertib+endocrine)				
	Initiation in Q4 '24				
Metastatic EGFR-mutant NSCLC****	NCT04085315 (alisertib+osimertinib)				
Small cell lung cancer	NCT02038647 (paclitaxel + alisertib)				
	ALISCA™-Lung1 (PUMA-ALI-4201)				
	Initiated in Q1'24				

*